Cargando…
Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients
AIM: To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma). METHODS: An open-label prospective clinical trial with 153 newly...
Autores principales: | Sun, Yuanyuan, Li, Ling, Li, Xin, Zhang, Lei, Wang, Xinhua, Fu, Xiaorui, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Yu, Hui, Chang, Yu, Yan, Jiaqin, Wu, Xiaolong, Zhou, Zhiyuan, Nan, Feifei, Tian, Li, Zhang, Mingzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278096/ https://www.ncbi.nlm.nih.gov/pubmed/32550864 http://dx.doi.org/10.1177/1758835920923829 |
Ejemplares similares
-
Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
por: Liu, Xiangli, et al.
Publicado: (2019) -
Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases
por: Du, Lijun, et al.
Publicado: (2020) -
Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study
por: Ma, Qianwen, et al.
Publicado: (2019) -
S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine
por: Zhou, Zhiyuan, et al.
Publicado: (2016) -
AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
por: Yan, Jiaqin, et al.
Publicado: (2018)